Market Assessment, Glomerulonephritis Current Treatment US 2016 Report

Glomerulonephritis (GN) is a condition involving inflammation of the glomerulus, which plays an important role in the filtration of blood into the kidney. If the glomerulus becomes inflamed and damaged, there can be a decline in kidney function leading to chronic kidney disease (CKD). This content provides a deep dive into the dynamics of the GN market, examining the management of GN patients from the perspective of nephrologists. We focus on how GN disorders such as immunoglobulin A (IgA) nephropathy, focal segmental glomerulosclerosis (FSGS), lupus nephritis, and idiopathic membranous glomerulonephritis (IMGN) are being treated in the United States today and on the factors behind those treatment decisions.

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Glomerulonephritis | Current Treatment | US | 2016

Related Market Assessment Reports

Migraine – Current Treatment – Detailed, Expanded Analysis (EU5)

Non-Small-Cell Lung Cancer – Current Treatment – Detailed, Expanded Analysis (US)

Breast Cancer – Unmet Need – Detailed, Expanded Analysis: Advanced Or Metastatic HER2-Positive Breast Cancer (US/EU)

Heart Failure – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Heart Failure – Preserved Ejection Fraction (US)

Male Hypogonadism – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Male Hypogonadism (Low Testosterone) (US)